Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $53.3 million.

  • Viking Therapeutics' Accounts Payables rose 44265.77% to $53.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $53.3 million, marking a year-over-year increase of 44265.77%. This contributed to the annual value of $53.3 million for FY2025, which is 44265.77% up from last year.
  • Viking Therapeutics' Accounts Payables amounted to $53.3 million in Q4 2025, which was up 44265.77% from $4.4 million recorded in Q3 2025.
  • Viking Therapeutics' Accounts Payables' 5-year high stood at $53.3 million during Q4 2025, with a 5-year trough of $254000.0 in Q3 2024.
  • Its 5-year average for Accounts Payables is $7.7 million, with a median of $5.4 million in 2024.
  • Its Accounts Payables has fluctuated over the past 5 years, first plummeted by 9555.24% in 2024, then surged by 163740.16% in 2025.
  • Viking Therapeutics' Accounts Payables (Quarter) stood at $1.4 million in 2021, then surged by 490.65% to $8.5 million in 2022, then fell by 11.92% to $7.5 million in 2023, then skyrocketed by 30.63% to $9.8 million in 2024, then skyrocketed by 442.66% to $53.3 million in 2025.
  • Its Accounts Payables stands at $53.3 million for Q4 2025, versus $4.4 million for Q3 2025 and $5.5 million for Q2 2025.